🔍

TTK Healthcare Limited (TTKHLTCARE)

₹1,035.00 +0.22% last close, 16 Oct

📊 NSE: TTKHLTCARE 🏢 Diversified - Medium / Small 📢 Latest filing: 04 Sep 2026 📝 Analysis written: 14 Dec 2025

Latest quarterly results (Q4 FY26)

In its latest reported quarter, Q4 FY26, TTK Healthcare's revenue was ₹218 Cr (+14.7% year on year, +4.3% on the previous quarter), and net profit ₹22.0 Cr (+37.5% year on year); the operating margin was 5.0%.

Q4 FY26 (₹ Cr)	Value	YoY vs Q4 FY25	QoQ
Revenue	₹218	+14.7%	+4.3%
Operating profit	₹11.0	-8.3%	+57.1%
Net profit	₹22.0	+37.5%	+100.0%
EPS (₹)	15.40	+34.7%	+106.7%
Operating margin	5.0%	—	—

Full quarterly financials → Results calendar →

TTKHLTCARE delivery percentage

NSE end-of-day data for Fri, 16 Oct 2026

On Fri, 16 Oct 2026, 61.97% of the TTKHLTCARE shares traded on NSE were taken to delivery, against the stock's own 20-session average of 53.66%. That is higher than usual for this stock. Turnover was only ₹53 lakh, so a handful of trades can move this figure. Volume was 0.1 times its average, well below normal.

61.97%Delivery, 16 Oct

53.66%Own 20-session average

0.1×Volume vs its average

₹1,035.00NSE close · +0.22%

Delivery in the last 5 sessions: 64.4% · 51.1% · 54.0% · 52.4% · 62.0%

Delivery across the market →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

TTK Healthcare Completes Sale of EVA & Good Home Brands for ₹256 Cr Cash

🟢 POSITIVE ⭐ 9/10

M&A 📅 04 Sep 2026, 02:50 PM

TTK Healthcare has completed the sale of its 'EVA' and 'Good Home' brands to Wipro Enterprises Private Limited, receiving a cash consideration of ₹256 crore plus applicable GST. The transaction closes the definitive agreement executed on July 23, 2026. The ₹256 crore cash inflow represents approximately 29.9% of TTM revenue (₹857 crore) and 16.4% of the company's market capitalization (₹1,557 crore). This significantly boosts the company's existing cash reserves, which previously stood high following its human pharma divestment.

Received ₹256 crore plus applicable GST in cash consideration on September 04, 2026
Divestment of 'EVA' and 'Good Home' brands to Wipro Enterprises stands completed
Definitive agreements were previously signed on July 23, 2026
Deal consideration represents ~29.9% of TTM revenue of ₹857 crore

💡 Watch for management commentary in the upcoming quarterly results regarding capital allocation plans, special dividend distribution, or potential redeployment of the cash surplus.

TTK Healthcare Appoints M/s. R V K & Co as Tax Auditor for 3 Years (FY26 to FY28)

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 02 Sep 2026, 02:37 PM

TTK Healthcare Limited has approved the appointment of M/s. R V K & Co., Chartered Accountants, as its Tax Auditor. The appointment is for a period of three financial years spanning FY 2025-26 to FY 2027-28. The firm is peer-reviewed and has over 12 years of standing. This is a routine statutory appointment with no operational or financial disruption to the company.

Appointment of M/s. R V K & Co as Tax Auditor approved by the Board based on Audit Committee recommendation
Tenure spans 3 financial years, covering FY 2025-26 through FY 2027-28
Appointed audit firm holds ICAI Peer Review certification and over 12 years of industry experience

💡 Track upcoming quarterly financial results and announcements regarding the deployment of the cash surplus from past divestments.

TTK Healthcare Tax Auditor M/s Aiyar & Co Resigns Effective August 26, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 27 Aug 2026, 03:47 PM

Tax auditor M/s. Aiyar & Co. has intimated its inability to continue as the Tax Auditor of TTK Healthcare Limited effective August 26, 2026. The resignation is due to ICAI Peer Review Certificate guidelines which render the firm ineligible to sign audit reports for listed entities. The assignment pertains to the tax audit report under Section 44AB of the Income Tax Act for FY 2025-26. The company's Audit Committee and Board will initiate the appointment of a replacement tax auditor shortly.

Tax auditor resignation took effect on August 26, 2026.
Scope pertains to the Tax Audit under Section 44AB of the Income Tax Act, 1961 for FY 2025-26.
Withdrawal driven by ICAI Peer Review Board eligibility criteria for listed entities.
Board and Audit Committee to appoint a replacement tax auditor shortly.

💡 Track the upcoming board disclosure regarding the appointment of a new tax auditor for FY 2025-26 to ensure tax filing compliance.

63% PAT Growth in Q1; TTK Healthcare to Sell EVA & Good Home Brands for Rs 256 Cr

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 06 Aug 2026, 01:22 PM

TTK Healthcare reported a strong Q1 FY26 with revenue growing 13.7% YoY to Rs 257.56 Cr and PAT rising 63.7% to Rs 21.28 Cr. A major highlight is the definitive agreement to sell the 'EVA' and 'Good Home' brands to Wipro Enterprises for Rs 256 Cr, representing approximately 30% of TTM revenue. The company also successfully recovered Rs 5.10 Cr from previously written-off USAID orders in the Protective Devices segment. Profitability was significantly bolstered by a turnaround in the Protective Devices division, which moved from a loss to a Rs 6.13 Cr profit.

Net Profit for Q1 FY26 rose to Rs 21.28 Cr from Rs 13.00 Cr in the same quarter last year.
Agreed to divest EVA and Good Home brands to Wipro Enterprises for Rs 256 Cr, expected to close by Sept 30, 2026.
Protective Devices segment profit turned around to Rs 6.13 Cr from a loss of Rs 5.44 Cr YoY.
Invoiced Rs 5.10 Cr worth of inventory to USAID that was previously written off in FY25.
Earnings Per Share (EPS) increased to Rs 15.06 for the quarter compared to Rs 9.20 in Q1 FY25.

💡 Monitor the completion of the Rs 256 Cr brand sale by September 30, 2026, and watch for management commentary on the deployment of the resulting cash surplus.

63.7% PAT Growth in Q1 FY26; TTK Healthcare to Sell Brands for ₹256 Cr

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 06 Aug 2026, 01:21 PM

TTK Healthcare reported a strong Q1 FY2026 with revenue growing 13.7% YoY to ₹257.56 cr and PAT increasing 63.7% to ₹21.28 cr. A major highlight is the definitive agreement to sell the 'EVA' and 'Good Home' brands to Wipro Enterprises for ₹256 cr, which represents approximately 30% of the company's TTM revenue. The company also recovered ₹5.10 cr from previously written-off USAID orders in the Protective Devices segment, boosting margins. With unallocated assets now at ₹976.23 cr, the company is exceptionally cash-rich relative to its ₹1,538 cr market cap.

Revenue from operations increased 13.7% YoY to ₹257.56 cr for the quarter ended June 30, 2026.
Net Profit surged 63.7% YoY to ₹21.28 cr compared to ₹13.00 cr in the same quarter last year.
Definitive agreement signed with Wipro Enterprises to sell EVA and Good Home brands for ₹256 cr.
Protective Devices segment revenue grew to ₹60.98 cr, supported by ₹5.10 cr in recovered USAID orders.
Unallocated assets (primarily cash/investments) reached ₹976.23 cr as of June 30, 2026.

💡 Monitor the completion of the brand sale transaction expected by September 30, 2026, and subsequent management commentary on the deployment of the ₹1,000 cr+ cash pile. Investors should also track if the margin improvement in the Protective Devices segment is sustainable post-USAID order recovery.

Rs 10 Dividend and 5-Year Chairman Re-appointment Approved at TTK Healthcare AGM

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 24 Jul 2026, 06:23 PM

TTK Healthcare shareholders have approved all resolutions at the 68th Annual General Meeting held on July 24, 2026. Key approvals include a dividend of Rs 10.00 per share for FY26 and the re-appointment of Mr. T T Raghunathan as Executive Chairman for a five-year term starting November 2026. The voting saw high participation with 81.13% of total shares polled, and nearly 100% of votes in favor of all resolutions. The company continues to operate with a significant cash surplus of approximately Rs 927 crore following its previous pharma division divestment.

Dividend of Rs 10.00 per share (100% on face value) approved for the financial year ended March 31, 2026.
Mr. T T Raghunathan re-appointed as Executive Chairman for a 5-year term effective November 1, 2026.
Total of 1,14,64,421 votes polled, representing 81.13% of the total 1,41,30,333 outstanding shares.
Promoter group participation was 100% with 1,05,35,840 votes cast in favor of all resolutions.
Public institutional participation was high at 96.64% of their holdings (5,53,666 votes).

💡 Investors should monitor the company's utilization of its Rs 927 crore cash surplus, which is earmarked for potential acquisitions or expansion to drive growth beyond the current 6.5% rate.

TTK Healthcare 68th AGM: Rs 10 Dividend Declared and Executive Chairman Re-appointed

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 24 Jul 2026, 02:49 PM

TTK Healthcare concluded its 68th Annual General Meeting on July 24, 2026, where shareholders voted on five key resolutions including the adoption of FY26 financial statements. A dividend of Rs 10.00 per share (100%) was declared, representing a yield of approximately 0.96% at current prices. A significant management decision included the re-appointment of Mr. T T Raghunathan as Executive Chairman for a further five-year term starting November 1, 2026. Management addressed operational queries from 13 shareholders, and the auditor's report contained no adverse qualifications.

Dividend of Rs 10.00 per share (100%) declared for the financial year ended March 31, 2026.
Re-appointment of Mr. T T Raghunathan as Executive Chairman for a 5-year term effective November 1, 2026.
Thirteen registered speaker members raised queries regarding the company's performance and operations.
The meeting was conducted via video conferencing and lasted approximately 65 minutes.
Auditor's Report for FY26 contained no qualifications or adverse comments on financial transactions.

💡 Investors should monitor the official voting results to be released within two working days and track the upcoming record date for the dividend payment.

₹256 Cr Brand Divestment and ₹900 Cr Cash Surplus Highlighted at 68th AGM

🟢 POSITIVE ⭐ 9/10

M&A 📅 24 Jul 2026, 02:49 PM

TTK Healthcare reported FY26 revenue of ₹857.28 cr, a 7% growth, though pre-tax profit fell to ₹82.56 cr due to the loss of USAID tender business in the Protective Devices segment. The company announced the divestment of its 'EVA' and 'Good Home' brands to Wipro Enterprises for ₹256 cr, which contributed ₹148 cr to FY26 revenue. Most notably, the company now holds a massive cash balance of ~₹900 cr, representing approximately 61% of its current market capitalization. A dividend of ₹10 per share (100%) was recommended.

Divestment of EVA and Good Home brands to Wipro for ₹256 cr plus GST
Cash and bank balances reached ~₹900 cr as of March 31, 2026
Ortho Division reported strong revenue growth of 27% in FY26
Divested brands (EVA and Good Home) had a combined turnover of ₹148 cr in FY26
Proposed pivotal clinical study for TC2 Titanium Heart Valve involving 400 patients

💡 Monitor the deployment strategy for the ₹900 cr cash surplus, as the company continues to divest non-core brands. Investors should track the margin impact of losing the ₹148 cr consumer brand revenue versus the interest income or acquisition potential from the new cash inflow.

₹256 Cr Brand Sale: TTK Healthcare to Divest EVA and Good Home Brands to Wipro

🟢 POSITIVE ⭐ 9/10

M&A 📅 23 Jul 2026, 01:03 PM

TTK Healthcare has signed definitive agreements to sell its 'EVA' and 'Good Home' brands to Wipro Enterprises for a total consideration of ₹256 crores. These brands contributed approximately ₹148 crores to the company's revenue in FY2025-26, accounting for 17% of total turnover. The transaction is expected to conclude by September 30, 2026, subject to customary closing conditions. This move further increases the company's significant cash reserves, which were already bolstered by a previous human pharma divestment.

Total sale consideration of ₹256 crores plus applicable GST
Divested brands contributed ₹148 crores (17%) to the FY2025-26 revenue
Transaction expected to be completed by September 30, 2026
Buyer is Wipro Enterprises Private Limited, a non-promoter third party
Sale consideration represents approximately 18% of the company's current market capitalization

💡 Investors should monitor the company's strategy for deploying its massive cash surplus, which now likely exceeds ₹1,000 crores, and watch for any margin improvements as the company streamlines its portfolio.

Rs 256 Cr Brand Sale: TTK Healthcare to Divest EVA and Good Home Brands to Wipro

🟢 POSITIVE ⭐ 9/10

M&A 📅 23 Jul 2026, 01:03 PM

TTK Healthcare has entered into a definitive agreement to sell its 'EVA' and 'Good Home' brands to Wipro Enterprises Private Limited for a total consideration of Rs 256 crore. These brands contributed approximately Rs 148 crore to the company's FY26 revenue, representing 17% of its total turnover. The transaction is expected to close by September 30, 2026, and will significantly increase the company's already substantial cash reserves. This move follows the company's previous large-scale divestment of its human pharma division.

Total sale consideration of Rs 256 crore plus applicable GST
Divested brands contributed Rs 148 crore (17%) to FY25-26 turnover
Transaction expected to be completed by September 30, 2026
Sale value represents approximately 18% of the company's current market capitalization of Rs 1,417 crore
Buyer is Wipro Enterprises Private Limited, a non-related party

💡 Investors should monitor the company's strategy for deploying its massive cash surplus, which now exceeds Rs 1,000 crore including previous divestment proceeds, as this will be the primary driver of future value.

Q1 FY27: TTK Healthcare Submits Routine SEBI Compliance Certificate

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 03 Jul 2026, 06:17 PM

TTK Healthcare has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the period ended June 30, 2026. The certificate, issued by the Registrar and Share Transfer Agent (RTA), M/s. Data Software Research Co. Pvt. Ltd., confirms that share certificates received for dematerialization were processed and records updated with NSDL and CDSL. This is a standard administrative filing required of all listed companies to ensure the integrity of shareholder records. There is no impact on the company's financial position or business operations.

Compliance certificate submitted for the first quarter ended June 30, 2026
Certificate issued by RTA M/s. Data Software Research Co. Pvt. Ltd. on July 03, 2026
Confirms adherence to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018
Filing confirms the cancellation of physical share certificates after dematerialization

💡 No action is required as this is a routine procedural filing. Investors should monitor the company's upcoming Q1 FY27 financial results for material performance updates.

TTK Healthcare Schedules 68th AGM; Proposes 100% Dividend and Chairman Re-appointment

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 27 Jun 2026, 02:52 PM

TTK Healthcare has released its FY2025-26 Annual Report and scheduled its 68th AGM for July 24, 2026. The company reported revenue from continuing operations of ₹929.43 crore, a growth of 6.5% over the previous year. A dividend of 100% (₹10 per share) has been proposed, consistent with the previous three years. A key agenda item is the re-appointment of Mr. T T Raghunathan as Executive Chairman for a five-year term starting November 1, 2026.

Revenue from continuing operations increased to ₹929.43 crore in FY26 from ₹872.75 crore in FY25.
Proposed dividend of 100% (₹10 per share) involving a total payout of ₹14.13 crore.
Net Current Assets reached ₹1,033.57 crore, largely comprising cash surpluses from the previous human pharma divestment.
Profit After Tax (PAT) for FY26 stood at ₹65.68 crore compared to ₹81.66 crore in FY25, which included exceptional items.
Re-appointment of Mr. T T Raghunathan as Executive Chairman for a term of 5 years until October 31, 2031.

💡 Investors should monitor the AGM for management commentary regarding the deployment of the ₹927 crore cash surplus, which is the primary catalyst for future growth or acquisitions.

TTK Healthcare Releases FY26 BRSR; Male Contraceptives Lead Revenue at 25.26%

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 27 Jun 2026, 02:52 PM

TTK Healthcare has submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26, providing a detailed breakdown of its diversified business segments. Male Contraceptives remain the largest revenue driver at 25.26%, followed by Food Products at 17.63% and Animal Welfare at 16.46%. The company maintains a lean export profile, with international sales contributing only 6.41% of total turnover. While the company operates 8 plants, it faces a high permanent employee turnover rate of 23.69%, which warrants monitoring regarding organizational stability.

Male Contraceptives constitute the largest business segment, accounting for 25.26% of total turnover.
Exports remain a minor part of the business, contributing 6.41% to the total turnover.
The company operates a network of 8 manufacturing plants and 41 offices across 28 states and 8 UTs.
Permanent employee turnover rate is relatively high at 23.69% for FY 2025-26.
Customer complaints showed a downward trend, decreasing to 176 from 213 in the previous year.

💡 Investors should focus on the deployment of the company's significant cash surplus (approx. Rs 927 Cr) for future growth, as the current BRSR confirms a reliance on existing niche segments with limited new capacity expansion.

TTK Healthcare schedules 68th AGM for July 24; proposes 100% dividend and Chairman reappointment

🟡 NEUTRAL ⭐ 4/10

BOARD_MEETING 📅 27 Jun 2026, 02:47 PM

TTK Healthcare has scheduled its 68th Annual General Meeting for July 24, 2026, to adopt FY26 financials and approve a 100% dividend (₹10 per share). The company reported FY26 revenue from continuing operations of ₹929.43 cr, a 6.5% increase over the previous year. A major agenda item is the reappointment of Mr. T T Raghunathan as Executive Chairman for a five-year term starting November 2026. The company maintains a significant liquidity position with Net Current Assets of ₹1,033.57 cr, largely comprising cash from its previous pharma division divestment.

Proposed dividend of 100% (₹10 per share) for the financial year ended March 31, 2026
FY26 Revenue from continuing operations stood at ₹929.43 cr compared to ₹872.75 cr in FY25
Net Current Assets reached ₹1,033.57 cr, representing approximately 78% of the company's market capitalization
Reappointment of Mr. T T Raghunathan as Executive Chairman for a 5-year term from November 1, 2026, to October 31, 2031
FY26 Profit After Tax (PAT) from continuing operations reported at ₹65.68 cr

💡 Investors should monitor the AGM proceedings for any management commentary regarding the deployment of the ₹802.8 cr cash surplus for future acquisitions or expansion.

TTK Healthcare Trading Window to Close from July 1, 2026 for Q1 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 22 Jun 2026, 05:22 PM

TTK Healthcare Limited has announced the closure of its trading window starting July 01, 2026, in compliance with SEBI Insider Trading regulations. This closure is in anticipation of the Unaudited Financial Results for the first quarter ending June 30, 2026. The restriction applies to all designated persons and their immediate relatives and will remain in effect until 48 hours after the results are declared. The specific date for the board meeting to approve these results will be communicated at a later date.

Trading window closure begins on July 01, 2026.
Closure is for the purpose of considering Unaudited Financial Results for the quarter ending June 30, 2026.
The window will reopen 48 hours after the official announcement of the financial results.
Designated persons and their immediate relatives are prohibited from trading during this period.

💡 No immediate action is required as this is a routine regulatory filing. Investors should look out for the upcoming board meeting date to evaluate the company's Q1 performance.

View All TTKHLTCARE Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Overall revenue grew 6.5% YoY to INR 801.5 Cr in FY2025 from INR 752.8 Cr in FY2024. Growth was reported across all divisions including Animal Welfare, Consumer Products, Food Products, Protective and Medical Devices. Q1 FY2026 revenue stood at INR 226.4 Cr.

Geographic Revenue Split

Not disclosed in available documents; however, the company maintains a wide distribution network across India.

Profitability Margins

Operating profit margins remained low at 4.5% in FY2025 (compared to 4.4% in FY2023) due to the distribution-heavy nature of the business. Margins significantly declined to 1.2% in Q1 FY2026 from 5.0% in Q1 FY2024, primarily due to higher sales promotion and branding expenses.

EBITDA Margin

EBITDA margin (OPBDIT/OI) was 4.5% in FY2025, up from 3.6% in FY2022 (excluding human pharma). The decline to 1.2% in Q1 FY2026 reflects a 380 bps YoY contraction due to competitive intensity.

Capital Expenditure

The company has planned maintenance capital expenditure of INR 10.0-12.0 Cr per annum for the FY2026-FY2028 period, to be funded through internal accruals.

Credit Rating & Borrowing

Long-term rating is [ICRA]A+ (Stable) as of September 2025. Short-term rating is [ICRA]A1+. Borrowing costs are minimal as the company is net-debt negative with only INR 22.6 Cr in working capital borrowings against INR 927.0 Cr in cash as of June 2025.

⚙️ Operational Drivers

Raw Materials

Not specifically disclosed, but the company operates an outsourcing model for most products except for Food Products, Medical, and Protective devices.

Capacity Expansion

Currently operates 6 manufacturing units. No major capacity expansion plans were disclosed beyond maintenance capex of INR 10-12 Cr per annum.

Raw Material Costs

Not disclosed as a specific percentage of revenue; however, the company's ability to pass on cost inflation is noted as a risk mitigation factor.

Logistics & Distribution

Not disclosed as a specific percentage; however, the 'distribution nature' of the business is cited as the primary reason for low operating margins (4.5%).

📈 Strategic Growth

Expected Growth Rate

6.50%

Growth Strategy

Growth will be driven by scaling up revenues to gain operating leverage, cost-optimization measures, and the potential deployment of the INR 802.8 Cr cash surplus from the human pharma divestment for future expansion or acquisitions.

Products & Services

Contraceptives, Woodward's Gripe Water, cosmetics, medical devices, home-care products, and ready-to-fry papads.

Brand Portfolio

TTK, Woodward's, TTK Healthcare.

Market Share & Ranking

Maintains a 'healthy market share' in key segments like contraceptives and gripe water, though specific percentages are not disclosed.

Strategic Alliances

Holds a 26% equity stake in BSV Pharma Private Limited following the divestment of its human pharma division.

🌍 External Factors

Industry Trends

The FMCG industry is shifting toward organically grown input materials, carbon neutrality, and stricter regulations regarding the usage of plastics in packaging.

Competitive Landscape

Faces intense competition from both large organized players and unorganized local manufacturers across all product segments.

Competitive Moat

Durable advantages include strong brand equity in niche categories (Gripe Water, Contraceptives), a well-entrenched pan-India distribution network, and the reputation of the TT Krishnamachari Group.

Consumer Behavior

Increasing health consciousness among consumers is impacting demand for certain traditional product categories.

⚖️ Regulatory & Governance

Industry Regulations

Subject to manufacturing standards for medical and protective devices, and environmental regulations for FMCG waste management.

Environmental Compliance

Exposed to evolving environmental norms regarding manufacturing residual discharge and restrictions on plastic packaging usage.

Legal Contingencies

No significant pending court cases or case values were disclosed in the auditor's report for FY2025.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the lack of clarity regarding the deployment of the INR 802.8 Cr cash surplus, which could significantly impact the company's future scale and rating.